In larger doses, the diabetes drug may increase height in children and adolescents.
The FDA has approved the FlexPro PenMate is intended for users of Norditropin, which is indicated for patients with growth hormone-related disorders, who prefer hidden needles during injection.
Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).
Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.
Young female athletes my experience endocrine disorders, including menstrual problems and difficulty with bone mass, due to intense training.
New study doubles the number of gene regions linked to height.
Endocrinology Advisor Articles
- Behavioral Weight Loss Interventions May Prevent Obesity
- Association Between Urine Complement Proteins and Kidney Disease, Mortality in T2D
- PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Availability and Affordability of Diabetes Medication Worldwide
- Estradiol, Cortisol, TGF-β1 Involved in Thyroid Immunity During Pregnancy and Postpartum
- Pharmacotherapy Personalization May Optimize Outcomes for Type 2 Diabetes
- Late-Onset Epilepsy Linked to Diabetes
- Examining the Ethical Considerations of Grateful Patient Fundraising
- Muscle Cell Proﬁles Relate to Exercise Response Variation in Type 2 Diabetes